KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Free Cash Flow (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Free Cash Flow for 17 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 22.25% to $2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.4 billion through Dec 2025, up 16.44% year-over-year, with the annual reading at $7.4 billion for FY2025, 16.44% up from the prior year.
  • Free Cash Flow hit $2.6 billion in Q4 2025 for Abbott Laboratories, up from $2.3 billion in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $2.6 billion in Q4 2025 to a low of $627.0 million in Q1 2024.
  • Historically, Free Cash Flow has averaged $1.8 billion across 5 years, with a median of $1.9 billion in 2022.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 530.99% in 2021 and later crashed 65.73% in 2023.
  • Year by year, Free Cash Flow stood at $2.5 billion in 2021, then crashed by 30.04% to $1.7 billion in 2022, then skyrocketed by 33.04% to $2.3 billion in 2023, then fell by 5.91% to $2.1 billion in 2024, then rose by 22.25% to $2.6 billion in 2025.
  • Business Quant data shows Free Cash Flow for ABT at $2.6 billion in Q4 2025, $2.3 billion in Q3 2025, and $1.5 billion in Q2 2025.